SCHEMBL15106961

SCHEMBL15106961

Cc1ccc(C(O)(c2ccccc2)C(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
XBP1 P17861 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ESR1 P03372 3/20 0.43
ESR2 Q92731 3/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP3A4 P08684 1/20 0.43
KIF11 P52732 8/20 0.43
LMNA P02545 2/20 0.42
ALOX12 P18054 1/20 0.42
ACHE P22303 1/20 0.42
CYP19A1 P11511 1/20 0.41
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7768882 0.89 MEN1 (0.50) TSHRMEN1KMT2ASMN1; SMN2XBP1
SCHEMBL2862802 0.89 MEN1 (0.50) TSHRMEN1KMT2ASMN1; SMN2XBP1
SCHEMBL15275691 0.89 ALDH1A1 (0.48) TSHRKMT2ASMN1; SMN2MAPK1ESR1
SCHEMBL5865830 0.85 NR1H2 (0.51) TSHRMEN1KMT2ASMN1; SMN2XBP1
SCHEMBL2239969 0.83 MEN1 (0.58) TSHRMEN1KMT2ASMN1; SMN2XBP1
SCHEMBL4457147 0.82 MEN1 (0.50) TSHRMEN1KMT2ASMN1; SMN2XBP1
SCHEMBL11475050 0.79 CYP19A1 (0.57) TSHRMEN1KMT2ASMN1; SMN2XBP1
SCHEMBL813126 0.79 CYP19A1 (0.57) TSHRMEN1KMT2ASMN1; SMN2XBP1
SCHEMBL2858670 0.78 CYP2C9 (0.50) TSHRMEN1KMT2ASMN1; SMN2XBP1
SCHEMBL7763633 0.78 TSHR (0.55) TSHRMEN1KMT2AMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-20130289235-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS, INC. (CA) 2013-10-31 US disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-20070299043-A1 Anti-scarring drug combinations and use thereof HUNTER WILLIAM L 2007-12-27 US disclosed
US-20070208134-A1 Anti-scarring drug combinations and use thereof HUNTER WILLIAM L 2007-09-06 US disclosed
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof ANGIOTECH INTERNATIONAL AG (CH) 2007-08-23 US disclosed
US-20070198063-A1 Electrical devices and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208134-A1 Anti-scarring drug combinations and use thereof MMP1, COL2A1, COL1A1 TSHR 3392/4885MEN1 3880/4885KMT2A 3554/4885
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof COL2A1, MMP1, FN1 TSHR 761/4885MEN1 2768/4885KMT2A 2943/4885
US-20070299043-A1 Anti-scarring drug combinations and use thereof MMP1, COL2A1, COL1A1 TSHR 3392/4885MEN1 3880/4885KMT2A 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.